Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Clinical trial NCT04486391 · TERMINATED

Trial details

NCT number: NCT04486391
Sponsor: BeiGene
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Classical Hodgkin Lymphoma

Start date: 2020-12-14
Primary completion: 2025-10-13
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.